Ministry of Health & Prevention Signs MoU with Biologix and Axios to Provide Drugs for Patients with Psoriatic Arthritis and MS

The Ministry of Health and Prevention (MoHAP) has signed lately, a Memorandum of Understanding (MoU) with Biologix and Axios Health Education Services, with a view to providing medications for low-income patients with multiple myeloma, psoriasis, Psoriatic arthritis and relapsing-remitting multiple sclerosis (RRMS). Around 260 patients will be benefitting from this new initiative.

The MoU comes in conjunction with the Year of Tolerance and pursuant to the “Sawa” program.

The MoU was signed at MoHAP headquarters by HE Dr. Amin Hussein Al Amiri, Assistant Undersecretary of the Ministry of Health and Prevention’s Public Health Policy and Licenses, Nabil Khoury, Operations Manager, Biologix and Anas Al-Safarini, Executive Director for the Middle East and North Africa, Axios Health Education Services.

Committed to Providing All Treatment Options for Patients

Dr. Ruqaya Al Bastaki, Director of Drug Department, said: “This humanitarian initiative is part of a series of initiatives launched by MoHAP in conjunction with the Year of Tolerance. It aims at providing drugs for the needy patients who aren’t covered by insurance, improving patients’ commitment to pursuing their treatment plan, supporting uninsured patients and those who don’t have prescriptions to obtain their treatment.”

She added that the initiative also includes patients who have partial insurance coverage or those without health insurance.

Ensuring Patients’ Eligibility for the Program

Axios will coordinate with charities and program partners such as licensed doctors, pharmacies and the drug agent supported by the program to ensure that the program is working seamlessly.

In addition to managing the program for eligible patients and communicating periodically with them to ensure that they receive the treatment according to the plan of each patient.

Axios will also evaluate the physical and social status of patients, to ensure their eligibility for both the program and the drug, as well as to identify the treatment support plans for each patient separately.

Community Responsibility

In turn, Nabil Khoury, Operations Manager, Biologix, emphasized the keenness of his company to contribute in patients support programs with a view to alleviating their suffering, particularly, those with low-income.

He added that this stems from Biologix’s commitment towards community responsibility, through the provision of a one-year medication according to a clear prescription by the doctor, hailing MoHAP’s efforts in providing medicines for needy patients.

Email This Post